Regulatory T cells in cancer immunotherapy

[1]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[2]  Dalya R. Soond,et al.  Corrigendum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer , 2016, Nature.

[3]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[4]  Ronald N. Germain,et al.  Immune homeostasis enforced by co-localized effector and regulatory T cells , 2015, Nature.

[5]  Bin Shang,et al.  Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis , 2015, Scientific Reports.

[6]  R. Balderas,et al.  Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans , 2015, Proceedings of the National Academy of Sciences.

[7]  Mark M. Davis,et al.  Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes. , 2015, Immunity.

[8]  D. Sugiyama,et al.  Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals , 2014, Science.

[9]  Marco Y. Hein,et al.  Continuous T cell receptor signals maintain a functional regulatory T cell pool. , 2014, Immunity.

[10]  A. Schäffer,et al.  Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations , 2014, Nature Medicine.

[11]  J. B. Oliveira,et al.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 , 2014, Science.

[12]  A. Rudensky,et al.  Continuous requirement for the T cell receptor for regulatory T cell function , 2014, Nature Immunology.

[13]  A. Witze.  Pluto-bound probe faces crisis , 2014, Nature.

[14]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[15]  Hiromasa Morikawa,et al.  Genetic and epigenetic basis of Treg cell development and function: from a FoxP3‐centered view to an epigenome‐defined view of natural Treg cells , 2014, Immunological reviews.

[16]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy. , 2014, Current opinion in immunology.

[17]  D. Campbell,et al.  CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets , 2014, The Journal of experimental medicine.

[18]  G. Nolan.  Leonard A. Herzenberg 1931–2013 , 2013, Nature Immunology.

[19]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[20]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[21]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[22]  Hiromasa Morikawa,et al.  Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression , 2013, Proceedings of the National Academy of Sciences.

[23]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[24]  Mark M Davis,et al.  Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. , 2013, Immunity.

[25]  K. Nakai,et al.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. , 2012, Immunity.

[26]  Shane J. Neph,et al.  Foxp3 Exploits a Pre-Existent Enhancer Landscape for Regulatory T Cell Lineage Specification , 2012, Cell.

[27]  M Roederer,et al.  T cell assays and MIATA: the essential minimum for maximum impact. , 2012, Immunity.

[28]  E. Jaffee,et al.  Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.

[29]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[30]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[31]  A. Schneeweiss,et al.  Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome , 2012, Cancer Immunology, Immunotherapy.

[32]  D. Price,et al.  A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.

[33]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[34]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[35]  J. Blay,et al.  Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL 22 production by tumor cells Running title : innate immune recognition trigger CCL 22 by breast tumor cells , 2011 .

[36]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[37]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[38]  Guobin Wang,et al.  Prognostic significance of regulatory T cells in tumor , 2010, International journal of cancer.

[39]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[40]  D. Sargent,et al.  Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. , 2009, Gastroenterology.

[41]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[42]  J. Wolchok,et al.  OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis , 2009, The Journal of experimental medicine.

[43]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[45]  P. Sharma,et al.  CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.

[46]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[47]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[48]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[49]  A. Rudensky,et al.  Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease , 2007, The Journal of experimental medicine.

[50]  T. Nomura,et al.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1 , 2007, Nature.

[51]  Ernest Fraenkel,et al.  Foxp3 occupancy and regulation of key target genes during T-cell stimulation , 2007, Nature.

[52]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[53]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[55]  J. Stroud,et al.  FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT , 2006, Cell.

[56]  K. Eguchi,et al.  Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. , 2006, Oncology reports.

[57]  S. Sakaguchi,et al.  Regulatory T cells in immune surveillance and treatment of cancer. , 2006, Seminars in cancer biology.

[58]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[60]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[62]  M. Manns,et al.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. , 2005, Cancer research.

[63]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[64]  T. Whiteside,et al.  Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.

[65]  Ethan M. Shevach,et al.  Engagement of Glucocorticoid-Induced TNFR Family-Related Receptor on Effector T Cells by its Ligand Mediates Resistance to Suppression by CD4+CD25+ T Cells , 2004, The Journal of Immunology.

[66]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[67]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[68]  William W. Kwok,et al.  Autoreactive T Cells in Healthy Individuals1 , 2004, The Journal of Immunology.

[69]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[70]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[71]  H. Fujii,et al.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  T. Sasada,et al.  CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies , 2003, Cancer.

[73]  D. Klatzmann,et al.  Continuous Activation of Autoreactive CD4+ CD25+ Regulatory T Cells in the Steady State , 2003, The Journal of experimental medicine.

[74]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[77]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[78]  M. Byrne,et al.  CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. , 2002, Immunity.

[79]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[80]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[81]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[82]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[83]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[84]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[85]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[86]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.